Results 241 to 250 of about 10,538,494 (333)

Mirikizumab pharmacokinetics and exposure–response in pediatric patients with moderate‐to‐severe ulcerative colitis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 474-485, March 2025.
Abstract Mirikizumab is a p19‐directed anti‐interleukin‐23 antibody approved for the treatment of adults with moderate‐to‐severe ulcerative colitis (UC). Here, we report the first data of mirikizumab pharmacokinetics (PK) and exposure–response (E/R) relationships in pediatric participants (aged 2 to <18 years weighing >10 kg) with moderate‐to‐severe UC
Yuki Otani, Laiyi Chua, Wendy J. Komocsar, Amy Larkin, Jordan Johns, Xin Zhang   +5 more
wiley   +1 more source

Epiglottic Ulceration as an Initial Manifestation of Crohn's Disease. [PDF]

J Gen Fam Med
Yamashita N, Morihisa Y, Nishioka H.
europepmc   +1 more source

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.

The Lancet, 2017
J. Colombel, R. Panaccione, P. Bossuyt, M. Lukáš, F. Baert, T. Vaňásek, A. Danalıoğlu, G. Novacek, A. Armuzzi, X. Hébuterne, S. Travis, S. Danese, W. Reinisch, W. Sandborn, P. Rutgeerts, D. Hommes, S. Schreiber, E. Neimark, Bidan Huang, Qian Zhou, Paloma Méndez, J. Petersson, Kori L Wallace, A. Robinson, R. Thakkar, G. D'Haens   +25 more
semanticscholar   +1 more source

The Role of Polyphenols in Respiratory and Gut Health: From the Perspective of Gut‐Lung Axis

Phytotherapy Research, EarlyView.
ABSTRACT The gut‐lung axis constitutes a dynamic, multidirectional communication platform between the gastrointestinal and respiratory tracts. Its complexity arises from the integrated crosstalk among the microbiota, immune system, and redox homeostasis, collectively influencing disease susceptibility and progression.
Jian Kang, YongJun Du, Yanmei Hou, Liangliang Hao, Zhen Chen, Haoyang Xie, Chuantao Zhang, Lei Li   +7 more
wiley   +1 more source

Observational study of metastatic vulvar Crohn's disease in the pediatric population. [PDF]

JPGN Rep
Winograd D, Addo A, Wassmer T, Hellmann J, Mallon D, Marathe K, Pennesi C.   +6 more
europepmc   +1 more source

Enteral nutritional therapy for induction of remission in Crohn's disease.

Cochrane Database of Systematic Reviews, 2018
N. Narula, A. Dhillon, Dongni Zhang, M. Sherlock, M. Tondeur, M. Zachos   +5 more
semanticscholar   +1 more source

Crohn??s Disease [PDF]

Journal of Occupational and Environmental Medicine, 1968
openaire   +2 more sources

Efficacy and Safety of Cannabis Derivates and Their Synthetic Analogs. Overview of Systematic Reviews

Phytotherapy Research, EarlyView.
ABSTRACT The use of medicinal products derived from cannabis and its synthetic analogues has grown in recent years for various health conditions, which led to an increase in systematic reviews (SR) on the topic. The objective of this overview was to identify, synthesize, and critically appraise the evidence from SR on the benefits and harms of cannabis
Rafael Leite Pacheco, Daniela Fortunato Rêgo, Carolina de Oliveira Cruz Latorraca, Marco Aurelio de Carvalho Nascimento, André Bastos Daher, Rachel Riera   +5 more
wiley   +1 more source

Advances in Crohn's Disease: A Comprehensive Review of Pathophysiology, Diagnosis, and Emerging Therapeutics. [PDF]

JGH Open
An YK, Gilmore R, Radford-Smith G, Begun J.   +3 more
europepmc   +1 more source

Betulinic Acid Enema Alleviates Colitis by Targeting Vitamin D Receptor to Protect the Intestinal Mucosal Barrier and Modulate Mucosa‐Associated Microbiota

Phytotherapy Research, EarlyView.
ABSTRACT Ulcerative colitis (UC) is a chronic inflammatory disease of the colon with limited effectiveness and safety of current drug therapies. Betulinic acid (BA) is a naturally occurring pentacyclic triterpenoid present in traditional Chinese medicines used clinically as retention enemas for UC, but its direct effects and mechanisms remain unclear ...
Lina Dong, Yuanxia Gao, Qian Li, Guangxin Chen, Dong Yang, Liping Zhao, Xiaojing Liu, Shumei Lin   +7 more
wiley   +1 more source